US1890541097 - Common Stock

We assign a fundamental rating of **4** out of 10 to **CLX**. **CLX** was compared to 12 industry peers in the **Household Products** industry. While **CLX** is still in line with the averages on profitability rating, there are concerns on its financial health. While showing a medium growth rate, **CLX** is valued expensive at the moment. **CLX** also has an excellent dividend rating.

In the past year **CLX** had a positive cash flow from operations.

In the past 5 years **CLX** has always been profitable.

Each year in the past 5 years **CLX** had a positive operating cash flow.

The **Return On Assets** of **CLX** (**1.35%**) is worse than **91.67%** of its industry peers.

The **Return On Equity** of **CLX** (**150.94%**) is better than **83.33%** of its industry peers.

The **Average Return On Invested Capital** over the past 3 years for **CLX** is in line with the industry average of **13.81%**.

The last **Return On Invested Capital** (**16.29%**) for **CLX** is above the 3 year average (**15.45%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.35% | ||

ROE | 150.94% | ||

ROIC | 16.29% |

ROA(3y)7.07%

ROA(5y)10.47%

ROE(3y)107.86%

ROE(5y)114.74%

ROIC(3y)15.45%

ROIC(5y)17.08%

In the last couple of years the **Profit Margin** of **CLX** has declined.

With a **Operating Margin** value of **12.68%**, **CLX** is not doing good in the industry: **66.67%** of the companies in the same industry are doing better.

The **Gross Margin** of **CLX** (**41.98%**) is better than **66.67%** of its industry peers.

In the last couple of years the **Gross Margin** of **CLX** has declined.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 12.68% | ||

PM (TTM) | 1.09% | ||

GM | 41.98% |

OM growth 3Y-16.55%

OM growth 5Y-9.83%

PM growth 3Y-47.54%

PM growth 5Y-31.57%

GM growth 3Y-4.8%

GM growth 5Y-2.08%

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so **CLX** is creating value.

An Altman-Z score of **3.62** indicates that **CLX** is not in any danger for bankruptcy at the moment.

The Debt to FCF ratio of **CLX** is **3.74**, which is a good value as it means it would take **CLX**, **3.74** years of fcf income to pay off all of its debts.

With a **Debt to FCF ratio** value of **3.74**, **CLX** is not doing good in the industry: **75.00%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 51.43 | ||

Debt/FCF | 3.74 | ||

Altman-Z | 3.62 |

ROIC/WACC1.93

WACC8.43%

The **Quick ratio** of **CLX** (**0.57**) is worse than **75.00%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 0.89 | ||

Quick Ratio | 0.57 |

The **Earnings Per Share** has been decreasing by **-2.03%** on average over the past years.

The **Revenue** has been growing slightly by **3.47%** in the past year.

Measured over the past years, **CLX** shows a small growth in **Revenue**. The Revenue has been growing by **3.83%** on average per year.

EPS 1Y (TTM)40.48%

EPS 3Y-11.53%

EPS 5Y-2.03%

EPS growth Q2Q120.41%

Revenue 1Y (TTM)3.47%

Revenue growth 3Y3.21%

Revenue growth 5Y3.83%

Revenue growth Q2Q16.03%

Based on estimates for the next years, **CLX** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **8.13%** on average per year.

The **Revenue** is expected to grow by **2.39%** on average over the next years.

EPS Next Y11.29%

EPS Next 2Y12.97%

EPS Next 3Y11.56%

EPS Next 5Y8.13%

Revenue Next Year0.08%

Revenue Next 2Y1.87%

Revenue Next 3Y2.29%

Revenue Next 5Y2.39%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The **Price/Earnings** ratio is **25.04**, which means the current valuation is very expensive for **CLX**.

When comparing the **Price/Earnings** ratio of **CLX** to the average of the S&P500 Index (**25.20**), we can say **CLX** is valued inline with the index average.

Based on the **Price/Forward Earnings** ratio of **22.47**, the valuation of **CLX** can be described as rather expensive.

The rest of the industry has a similar **Price/Forward Earnings** ratio as **CLX**.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 25.04 | ||

Fwd PE | 22.47 |

Based on the **Enterprise Value to EBITDA** ratio, **CLX** is valued a bit more expensive than 66.67% of the companies in the same industry.

Based on the **Price/Free Cash Flow** ratio, **CLX** is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 24.89 | ||

EV/EBITDA | 17.34 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

PEG (NY)2.22

PEG (5Y)N/A

EPS Next 2Y12.97%

EPS Next 3Y11.56%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.35% |

On average, the dividend of **CLX** grows each year by **6.15%**, which is quite nice.

Dividend Growth(5Y)6.15%

Div Incr Years19

Div Non Decr Years19

DP737.5%

EPS Next 2Y12.97%

EPS Next 3Y11.56%

**CLOROX COMPANY**

NYSE:CLX (4/23/2024, 7:04:00 PM)

After market: 144.311 -1.66 (-1.14%)**145.97**

**+0.83 (+0.57%) **

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupHousehold & Personal Products

GICS IndustryHousehold Products

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap18.12B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3.35% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 25.04 | ||

Fwd PE | 22.47 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)2.22

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.35% | ||

ROE | 150.94% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 12.68% | ||

PM (TTM) | 1.09% | ||

GM | 41.98% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.24

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 51.43 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 0.89 | ||

Quick Ratio | 0.57 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)40.48%

EPS 3Y-11.53%

EPS 5Y

EPS growth Q2Q

EPS Next Y11.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)3.47%

Revenue growth 3Y3.21%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y